A method for treating myocardial or skeletal muscle anoxia which occurs in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue. This method comprises the administration of a combination composition comprising (a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof; and (b) ribose or a phosphate derivative thereof.

Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose

Pietro; Pola

The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally.

Koverech; Aleardo

Use of L-carnitine for the treatment of cardiovascular diseases

The invention relates to compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.2 ' X, Y, Z, A, B, Q and n are as described herein. Their pharmaceutically acceptable salts, and when appropriate, enantiomers, racemates, diastereomers or mixtures thereof or geometric isomer or mixtures thereof, and pharmaceutically acceptable salts thereof. The compounds of formula I inhibit enzyme carnitine acyltransferase 1 (CAT-1) and are therefore useful in the prevention of injury to ischemic tissue, and can limit infarct size, improve cardiac function and prevent arrhythmias during and following a myocardial infarction.

carnitine/infark

Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose

Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose

Use of L-carnitine for the treatment of cardiovascular diseases

Cat-1 inhibitors, pharmaceutical compositions and methods of use

Database tanaman obat terlengkap yang didukung oleh sains